NASDAQ:AMPH

Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

$28.10

-0.89 (-3.07%)

(As of 09/30/2022 09:00 PM ET)

Add

Compare

Today's Range: $28.07
▼
$29.34
50-Day Range: $27.56
▼
$37.75
52-Week Range: $18.12
▼
$44.46

Volume: 312,000 shs
Average Volume: 442,782 shs
Market Capitalization: $1.38 billion

P/E Ratio: 15.79
Dividend Yield: N/A
Price Target: $38.50

Amphastar Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 37.0% Upside
$38.50 Price Target
Short Interest: Healthy
5.55% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.21
Upright™ Environmental Score
News Sentiment: 1.33
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.09 M Sold Last Quarter
Proj. Earnings Growth: 14.38%
From $1.46 to $1.67 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.94 out of 5 stars

Medical Sector

37th out of 1,095 stocks

Pharmaceutical Preparations Industry

9th out of 547 stocks

3.3

Analyst's Opinion

Consensus Rating
Amphastar Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.50, Amphastar Pharmaceuticals has a forecasted upside of 37.0% from its current price of $28.10.
Amount of Analyst Coverage
Amphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.55% of the float of Amphastar Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Amphastar Pharmaceuticals has recently decreased by 5.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Amphastar Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amphastar Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.
Environmental Sustainability
The Environmental Impact score for Amphastar Pharmaceuticals is -2.21.

3.5

News and Social Media Coverage

News Sentiment
Amphastar Pharmaceuticals has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Amphastar Pharmaceuticals this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,093,649.00 in company stock.
Percentage Held by Insiders
27.80% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.11% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Amphastar Pharmaceuticals are expected to grow by 14.38% in the coming year, from $1.46 to $1.67 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amphastar Pharmaceuticals is 15.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.41.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amphastar Pharmaceuticals is 15.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.50.
Price to Book Value per Share Ratio
Amphastar Pharmaceuticals has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock News Headlines

September 25, 2022 | reuters.com

Amphastar Pharmaceuticals Inc

September 23, 2022 | seekingalpha.com

AMPH Amphastar Pharmaceuticals, Inc.

September 5, 2022 | finance.yahoo.com

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

September 2, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

August 30, 2022 | nasdaq.com

Amphastar Pharmaceuticals Becomes Oversold (AMPH)

August 29, 2022 | msn.com

Amphastar Pharmaceuticals's Return on Invested Capital Overview

August 29, 2022 | nasdaq.com

Amphastar Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for AMPH

August 26, 2022 | marketwatch.com

Isoprenaline Market Share and Growth 2022 Research by Market Dynamics, Global Size, Latest Innovations, Trends and Future Insights till 2028

August 21, 2022 | nasdaq.com

Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Latest Stock Performance A Reflection Of Its Financial Health?

August 17, 2022 | finanznachrichten.de

Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

August 16, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

August 12, 2022 | marketwatch.com

Amphastar Pharma Shares Up 48.5% Since SmarTrend's Buy Recommendation (AMPH)

August 8, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals (AMPH) Q2 2022 Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

August 8, 2022 | finance.yahoo.com

Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill

August 8, 2022 | seekingalpha.com

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

August 1, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

July 31, 2022 | finance.yahoo.com

Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Recent Stock Performance Tethered To Its Strong Fundamentals?

July 30, 2022 | marketwatch.com

Enoxaparin Sodium Market 2022 Industry Size, Share, Growth Insights, Top Key Players, Future Scenario and Forecast to 2028

July 26, 2022 | finance.yahoo.com

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings

July 24, 2022 | nasdaq.com

Amphastar Pharmaceuticals' (NASDAQ:AMPH) investors will be pleased with their stellar 109% return over the last five years

July 19, 2022 | finanznachrichten.de

Amphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Vasopressin

July 19, 2022 | finance.yahoo.com

Amphastar Receives FDA Approval for Vasopressin

July 15, 2022 | finance.yahoo.com

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5

June 30, 2022 | finance.yahoo.com

Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Company Calendar

Last Earnings: 8/08/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMPH
CUSIP: N/A
CIK: 1297184
Web: www.amphastar.com
Phone: (909) 980-9484
Fax: 909-980-8296
Employees: 1,761
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $38.50
High Stock Price Forecast: $44.00
Low Stock Price Forecast: $32.00
Forecasted Upside/Downside: +37.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.78
Trailing P/E Ratio: 15.79
Forward P/E Ratio: 19.25
P/E Growth: N/A
Net Income: $62.12 million
Net Margins: 19.06%
Pretax Margin: 24.53%
Return on Equity: 18.51%
Return on Assets: 12.42%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 3.64
Quick Ratio: 2.69

Sales & Book Value

Annual Sales: $437.77 million
Price / Sales: 3.15
Cash Flow: $1.91 per share
Price / Cash Flow: 14.70
Book Value: $9.31 per share
Price / Book: 3.02

Miscellaneous

Outstanding Shares: 49,015,000
Free Float: 35,389,000
Market Cap: $1.38 billion
Optionable: Optionable
Beta: 0.72

Key Executives

Dr. Ziping Luo Ph.D. (Age 72)
Chairman, Chief Scientist & COO
Comp: $1.34M

Dr. Yongfeng Zhang Ph.D. (Age 75)
Co-Founder, Pres, CEO, Chief Scientific Officer & Director
Comp: $1.93M

Mr. William J. Peters M.B.A. (Age 54)
CFO, Exec. VP of Fin., Treasurer & Director
Comp: $1.11M

Mr. Jacob Liawatidewi M.B.A. (Age 48)
Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director
Comp: $773.69k

Mr. Rong Zhou M.S. (Age 63)
Exec. VP of Production Center
Comp: $842.77k

Dan Dischner M.B.A.
VP of HR & Corp. Communication

Tony Marrs M.B.A.
M.P.H., Sr. VP of Regulatory Affairs & Clinical Operations

Mr. Peter Langosh (Age 69)
VP of Operational Improvement and VP of Internal Audit

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMPH Stock - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings or view top-rated stocks.
What is Amphastar Pharmaceuticals' stock price forecast for 2022?: 3 Wall Street analysts have issued 1-year price targets for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they expect the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts.
How have AMPH shares performed in 2022?: Amphastar Pharmaceuticals' stock was trading at $23.29 at the beginning of the year. Since then, AMPH stock has increased by 20.7% and is now trading at $28.10.
View the best growth stocks for 2022 here.
When is Amphastar Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AMPH earnings forecast.
How were Amphastar Pharmaceuticals' earnings last quarter?: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings results on Monday, August, 8th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.30 by $0.03. The company earned $123.47 million during the quarter, compared to analyst estimates of $118.17 million. Amphastar Pharmaceuticals had a net margin of 19.06% and a trailing twelve-month return on equity of 18.51%. During the same quarter in the previous year, the business posted $0.21 EPS.
What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?: 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).
What is Amphastar Pharmaceuticals' stock symbol?: Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How do I buy shares of Amphastar Pharmaceuticals?: Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amphastar Pharmaceuticals' stock price today?: One share of AMPH stock can currently be purchased for approximately $28.10.
How much money does Amphastar Pharmaceuticals make?: Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.38 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.78 on an earnings per share basis.
How many employees does Amphastar Pharmaceuticals have?: The company employs 1,761 workers across the globe.
How can I contact Amphastar Pharmaceuticals?: Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

Amphastar Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

AMPH Stock News Headlines

AMPH Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMPH Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™